

SUPPLEMENTARY INFORMATION

Synthesis and biological activities of ferrocenyl derivatives of paclitaxel

Damian Plażuk,^{*a} Anna Wieczorek^a, Andrzej Blauż^b and Błażej Rychlik^b

^a Department of Organic Chemistry, Faculty of Chemistry, University of Łódź, Tamka 12, 91-403 Łódź, Poland. Fax: +4842 ; Tel: +4842 6355760; E-mail: damplaz@uni.lodz.pl

^b Cytometry Lab, Department of Molecular Biophysics, Faculty of Biology and Environmental Protection, University of Łódź, 12/16 Banacha St. 90-237 Łódź, Poland.

Contents

Experimental:	S2
General procedure of acylation of taxoids with ferrocene acids	S2
2'-ferrocenoylpaclitaxel 3	S2
2'-(3-ferrocenoylpropiolyl)paclitaxel 4	S3
2'-ferrocenoyldocetaxel 5	S4
2'-(3-ferrocenoylpropiolyl)docetaxel 6	S4
Cytotoxic activity	S5
Tubulin affinity	S6
 Viability of cancer cells	
Figure S1. Viability of cancer cell lines in the presence of 1	S6
Figure S2. Viability of cancer cell lines in the presence of 3	S6
Figure S3. Viability of cancer cell lines in the presence of 4	S7
Figure S4. Viability of cancer cell lines in the presence of 5	S7
Figure S5. Viability of cancer cell lines in the presence of 6	S8
Figure S6. Viability of cancer cell lines in the presence of 2	S8
Figure S7. Viability of SW620D cell line in the presence of 2 , 5 and 6	S9

Figure S8. Viability of SW620E cell line in the presence of 2 , 5 and 6	S9
Copies of ^1H and ^{13}C NMR spectra of 3	S10
Copies of ^1H and ^{13}C NMR spectra of 4	S12
Copies of ^1H and ^{13}C NMR spectra of 5	S14
Copies of ^1H and ^{13}C NMR spectra of 6	S16
Copies of MALDI-MS spectra of 3	S18
Copies of MALDI-MS spectra of 4	S19
Copies of MALDI-MS spectra of 5	S20
Copies of MALDI-MS spectra of 6	S21

Experimental

Commercially available solvents (HPLC grade – ALDRICH) and reagents (ALDRICH or AKSCI (USA) or HBCChem (USA)) were used as received. Microanalyses (C, H, and N) and MS spectra were performed at The Centre of Molecular and Macromolecular Studies in Łódź (Polish Academy of Sciences), Poland. MS spectra (MALDI-TOF) were recorded on Voyager-Elite, PerSeptive Biosystems Inc. (Framingham, MA, USA), pulse laser at 337 nm was used. ^1H and ^{13}C nuclear magnetic resonance spectra were recorded on Bruker Avance III 600 MHz spectrometer operating at 600.26 and 150.95 MHz respectively. Chemical shifts were determined relative to the solvent residual peaks.

Synthesis

General procedure of acylation of taxoids with ferrocene acids.

2'-ferrocenoylpaclitaxel **3**

To a solution of 85.4 mg (0.10 mmol) of paclitaxel **1** and 25.4 mg (0.11 mmol) of ferrocenecarboxylic acid and 13 mg (0.11 mmol) of DMAP in 5 ml of anhydrous dichloromethane, diisopropylcarbodiimide (DIC) (25.2 mg, 0.20 mmol, 31 μl) was added and the resulted solution was stirred at 0°C. After 4 h the organic solvent was evaporated and the product was purified by chromatography on silica gel (50 g) using n-hexane – ethyl acetate 1-1 as eluent. Yield: 71 mg, 67%, of an orange crystals.

^1H NMR (600.26 MHz, CDCl_3): δ 1.15 (3 H, s), 1.25 (3 H, s), 1.70 (3 H, s), 1.90 (1 H, t, $J=12.23$ Hz), 2.03 (3 H, s), 2.14 (1 H, dd, $J=15.25, 8.85$ Hz), 2.23 (3 H, s), 2.38 (1 H, dd,

$J=15.25, 9.22$ Hz), 2.50 (3 H, s), 2.58 (1 H, ddd, $J=15.06, 9.03, 6.78$ Hz), 3.85 (1 H, d, $J=6.78$ Hz), 4.15 (5 H, s), 4.22 (1 H, d, $J=8.28$ Hz), 4.33 (1 H, d, $J=8.28$ Hz), 4.47 (3 H, br. s.), 4.79 (1 H, br. s.), 4.82 (1 H, br. s.), 4.99 (1 H, d, $J=9.03$ Hz), 5.55 (1 H, d, $J=3.01$ Hz), 5.70 (1 H, d, $J=7.15$ Hz), 6.00 (1 H, d, $J=6.40$ Hz), 6.28 - 6.31 (1 H, m), 6.33 (1 H, s), 7.00 (1 H, d, $J=8.28$ Hz), 7.33 - 7.38 (1 H, m), 7.42 - 7.49 (6 H, m), 7.51 - 7.56 (3 H, m), 7.59 - 7.66 (1 H, m), 7.81 (2 H, d, $J=7.53$ Hz), 8.14 (2 H, d, $J=7.53$ Hz)

^{13}C NMR (150.95 MHz, CDCl_3): δ 9.61, 14.18, 14.91, 20.80, 22.17, 22.76, 26.82, 35.51, 35.63, 43.18, 45.60, 53.13, 58.54, 60.36, 68.84, 69.99, 70.14, 70.35, 71.69, 71.90, 72.01, 72.11, 74.13, 75.16, 75.62, 76.43, 79.22, 81.08, 84.46, 126.42, 127.02, 128.49, 128.73, 128.80, 129.10, 129.22, 130.21, 132.02, 132.70, 133.64, 133.83, 137.29, 143.00, 167.04, 168.22, 169.75, 170.86, 171.10, 171.22, 203.83

IR (KBr) $\nu_{\text{max}}/\text{cm}^{-1}$: 3447 (NH), 1720 (C=O)

Elemental analysis calculated for $\text{C}_{58}\text{H}_{59}\text{FeNO}_{15}$ C-65.35, H - 5.58, N - 1.31 found C - 65.40, H - 5.62, N - 1.28

MS (MALDI, HCHA): calculated for $\text{C}_{58}\text{H}_{59}\text{FeNO}_{15}$: 1065.32, found: 1065.28

2'-(3-ferrocenoylpropiolyl)paclitaxel 4

It was prepared in the same method as **3** starting from 3-ferrocenoylpropionic acid (32mg, 0.2 mmol) instead of ferrocenecarboxylic acid. Yield: 77.4 mg, 69% (orange crystals).

^1H NMR (600.26 MHz, CDCl_3): δ 1.14 (3 H, s), 1.23 (3 H, s), 1.68 (3 H, s), 1.82 (1 H, br. s.), 1.86 (1 H, s), 1.87 - 1.90 (1 H, m), 1.93 (3 H, s), 2.14 (1 H, dd, $J=15.43, 9.03$ Hz), 2.22 (3 H, s), 2.34 (1 H, dd, $J=15.43, 9.41$ Hz), 2.44 (3 H, s), 2.49 (1 H, br. s.), 2.51 - 2.58 (1 H, m), 2.79 - 2.86 (2 H, m), 2.99 - 3.06 (1 H, m), 3.06 - 3.14 (1 H, m), 3.81 (1 H, d, $J=6.78$ Hz), 4.22 (5 H, s), 4.31 (1 H, d, $J=8.28$ Hz), 4.39 - 4.46 (1 H, m), 4.52 (2 H, d, $J=1.13$ Hz), 4.77 (2 H, dd, $J=8.66, 1.13$ Hz), 4.96 (1 H, d, $J=8.66$ Hz), 5.52 (1 H, d, $J=3.76$ Hz), 5.68 (1 H, d, $J=7.15$ Hz), 5.95 (1 H, dd, $J=8.66, 3.39$ Hz), 6.25 (1 H, t, $J=8.85$ Hz), 6.28 (1 H, s), 7.08 (1 H, d, $J=8.66$ Hz), 7.33 (1 H, td, $J=5.46, 2.63$ Hz), 7.40 - 7.45 (6 H, m), 7.49 - 7.55 (3 H, m), 7.59 - 7.64 (1 H, m), 7.80 (2 H, d, $J=7.15$ Hz), 8.14 (2 H, d, $J=7.53$ Hz)

^{13}C NMR (150.95 MHz, CDCl_3): δ 9.94, 14.18, 21.01, 22.60, 23.47, 26.37, 27.47, 28.16, 33.87, 35.58, 36.87, 42.16, 43.10, 46.41, 57.60, 60.33, 69.11, 69.29, 69.94, 71.79, 71.86, 72.29, 72.31, 74.49, 74.58, 75.06, 76.56, 78.24, 78.91, 80.33, 80.99, 84.22, 126.50, 128.17,

128.68, 128.86, 129.27, 130.18, 133.60, 135.52, 139.18, 156.90, 167.06, 168.14, 169.65,
171.13, 172.20, 201.47, 211.58

IR (KBr) $\nu_{\text{max}}/\text{cm}^{-1}$: 3432 (NH), 1741 (C=O), 1725 (C=O)

Elemental analysis calculated for $\text{C}_{61}\text{H}_{63}\text{FeNO}_{16}$ C-65.30, H – 5.66, N – 1.25 found C – 65.18,
H – 5.72, N – 1.38

MS (MALDI, HCHA): calculated for $\text{C}_{61}\text{H}_{63}\text{FeNO}_{16}$: 1121.35, found: 1121.45

2'-ferrocenoyldocetaxel 5

It was prepared in the same method as **3** starting from docetaxel (80.5 mg, 0.10 mmol) instead of paclitaxel. Yield: 67mg, 66% (orange crystals).

^1H NMR (600.26 MHz, CDCl_3): δ 1.14 (3 H, s), 1.25 (3 H, s), 1.37 (9 H, s), 1.67 (3H, s), 1.77 (3 H, s), 1.87 (1 H, t, $J=12.42$ Hz), 2.03 (3 H, s), 2.11 - 2.19 (1 H, m), 2.34 (1 H, br. s.), 2.48 (3 H, br. s.), 2.56 - 2.65 (1 H, m), 3.97 (1 H, d, $J=7.15$ Hz), 4.11 (5 H, s), 4.19 - 4.25 (2 H, m), 4.29 (1 H, d, $J=4.52$ Hz), 4.34 (1 H, d, $J=8.66$ Hz), 4.44 (2 H, br. s.), 4.76 (1 H, br. s.), 4.81 (1 H, br. s.), 4.99 (1 H, d, $J=9.04$ Hz), 5.25 (1 H, s), 5.43 (1 H, br. s.), 5.55 (1 H, br. s.), 5.71 (1 H, d, $J=7.15$ Hz), 6.25 - 6.35 (1 H, m), 7.30 - 7.35 (1 H, m), 7.38 - 7.42 (2 H, m), 7.43 - 7.47 (2 H, m), 7.52 (2 H, t, $J=7.72$ Hz), 7.60 - 7.64 (1 H, m), 8.13 (2 H, d, $J=7.53$ Hz)

^{13}C NMR (150.95 MHz, CDCl_3): δ 9.95, 14.15, 20.93, 20.99, 22.68, 26.34, 28.17, 35.58, 36.85, 43.09, 46.42, 57.57, 60.36, 68.92, 69.98, 70.10, 70.44, 71.71, 71.80, 71.85, 74.37, 74.48, 75.09, 76.54, 78.95, 81.00, 84.23, 126.24, 128.18, 128.66, 128.91, 129.30, 130.16, 133.57, 135.43, 167.02, 168.14, 169.69, 170.95, 171.13, 211.53,

IR (KBr) $\nu_{\text{max}}/\text{cm}^{-1}$: 3447 (NH), 1720 (C=O)

Elemental analysis calculated for $\text{C}_{54}\text{H}_{61}\text{FeNO}_{15}$ C-63.59, H – 6.03, N – 1.37 found C – 63.52,
H – 6.11, N – 1.42

MS (MALDI, HCHA): calculated for $\text{C}_{54}\text{H}_{61}\text{FeNO}_{15}$: 1119.34, found: 1119.34

2'-(3-ferrocenoylpropiolyl)docetaxel 6

It was prepared in the same method as **4** starting from docetaxel (80.5 mg, 0.10 mmol) instead of paclitaxel. Yield: 74 mg, 69% (orange crystals).

^1H NMR (600.26 MHz, CDCl_3) δ 1.13 (3 H, s), 1.24 (3 H, s), 1.35 (9 H, s), 1.68 (2 H, s), 1.75 (3 H, s), 1.85 (1 H, t, $J=12.42$ Hz), 1.95 (3 H, s), 2.05 (2 H, s), 2.14 - 2.22 (1 H, m), 2.32 (1 H, br. s.), 2.43 (3 H, br. s.), 2.53 - 2.61 (1 H, m), 2.75 - 2.83 (2 H, m), 2.94 - 3.01 (1 H, m), 3.03 - 3.11 (1 H, m), 3.94 (1 H, d, $J=6.78$ Hz), 4.17 - 4.21 (2 H, m), 4.23 (5 H, s), 4.33 (1 H, d, $J=8.66$ Hz), 4.52 (2 H, s), 4.78 (1 H, br. s.), 4.80 (1 H, br. s.), 4.96 (1 H, d, $J=9.03$ Hz), 5.20 (1 H, s), 5.37 (1 H, br. s.), 5.45 (2 H, br. s.), 5.70 (1 H, d, $J=6.78$ Hz), 6.26 (1 H, br. s.), 7.33 (3 H, d, $J=7.53$ Hz), 7.38 - 7.43 (2 H, m), 7.48 - 7.54 (2 H, m), 7.59 - 7.64 (1 H, m), 8.13 (2 H, d, $J=7.53$ Hz)

^{13}C NMR (150.95 MHz, CDCl_3) δ 211.58, 201.47, 172.20, 171.13, 169.65, 168.14, 167.06, 156.90, 139.18, 135.52, 133.60, 130.18, 129.27, 128.86, 128.68, 128.17, 126.50, 84.22, 80.99, 80.33, 78.91, 78.24, 76.56, 75.06, 74.58, 74.49, 72.31, 72.29, 71.86, 71.79, 69.94, 69.29, 69.11, 60.37, 57.60, 46.41, 43.10, 42.20, 36.87, 35.58, 33.84, 28.16, 27.47, 26.37, 22.60, 20.89, 14.18, 9.94,

IR (KBr) $\nu_{\text{max}}/\text{cm}^{-1}$: 3442 (NH), 1741 (C=O), 1717 (C=O)

Elemental analysis calculated for $\text{C}_{57}\text{H}_{65}\text{FeNO}_{16}$ C-63.63, H – 6.09, N – 1.30 found C – 63.57, H – 6.28, N – 1.24

MS (MALDI, HCHA): calculated for $\text{C}_{57}\text{H}_{65}\text{FeNO}_{16}$: 1075.67, found: 1075.37

Cytotoxic activity

The sensitivity of the parental and multidrug-resistant cancer cell lines was determined by a modified MTT-reduction assay. Shortly, the cells suspended in 100 μl of medium were seeded on the 96-well plates at the density of 5000 cells/well. The cells were allowed to attach for 24 hours and then the investigated compounds at the desired concentration was administered. The stock solutions of the taxanes were prepared in dimethylsulphoxide (DMSO) and care was taken to keep solvent concentration equal in all wells including controls. The final DMSO concentration did not exceed 0.1% v/v and was proven to be non-toxic to the cells. After 70 hours of incubation, MTT was added to the medium to a final concentration of 1.1 mmole/l. After further 2 hours the medium was removed and the formazane crystals were dissolved in 100 μl of DMSO. The absorbance was measured at 580 nm analytical wavelength and 720 nm reference wavelength. The results were turned into percentage of controls and the IC_{50} values for each cell line and drug were calculated by GraphPad Prism 4.03 software (GraphPad Inc. La Jolla, California, USA).

Tubulin affinity

The tubulin affinity was measured with Tubulin Polymerization Assay Biochem Fluorescence Based Kit (Cytoskeleton Inc., Denver, Colorado, USA) according to the manufacturer's instructions. The investigated compounds were added to a reaction medium in a final concentration range from 0.6 up to 3.0 μM . The tubulin polymerization rate was determined from the linear portion of a polymerization curve and plotted against the drug concentration. The affinity constant was calculated by GraphPad Prism 4.03 software (GraphPad Inc. La Jolla, California, USA).




Figure S1. Viability of cancer cell lines in the presence of **1**




Figure S2. Viability of cancer cell lines in the presence of **3**




Figure S3. Viability of cancer cell lines in the presence of 4




Figure S4. Viability of cancer cell lines in the presence of 5




Figure S5. Viability of cancer cell lines in the presence of 6




Figure S6. Figure S1. Viability of cancer cell lines in the presence of 2




Figure S7. Viability of SW620D cell line in the presence of **2**, **5** and **6**




Figure S8. Viability of SW620E cell line in the presence of **2**, **5** and **6**

¹H NMR of 3




Current Data Parameters
NAME dp-11-052
EXPNO 12
PROCNO 1


F2 - Acquisition Parameters
Date_ 20111212
Time 18.53
INSTRUM spect
PROBHD 5 mm PABBO BB-
PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 12335.526 Hz
FIDRES 0.188225 Hz
AQ 2.6564426 sec
RG 90.5
DW 40.533 usec
DE 8.50 usec
TE 302.0 K
D1 1.00000000 sec
TD0 1

===== CHANNEL f1 =====
NUC1 1H
P1 9.40 usec
PL1 -3.00 dB
PL1W 30.57242203 W
SFO1 600.2637069 MHz

F2 - Processing parameters
SI 32768
SF 600.2600175 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00



¹³C NMR of 3



Current Data Parameters
NAME dp-11-052
EXPNO 10
PROCNO 1

F2 - Acquisition Parameters
Date_ 20111212
Time 18.39
INSTRUM spect
PROBHD 5 mm PABBO BB-
PULPROG zgpg30
TD 65536
SOLVENT CDCl3
NS 1024
DS 4
SWH 36057.691 Hz
FIDRES 0.550197 Hz
AQ 0.9088159 sec
RG 2050
DW 13.867 usec
DE 8.50 usec
TE 302.0 K
D1 2.00000000 sec
D11 0.03000000 sec
TD0 1

===== CHANNEL f1 =====
NUC1 13C
P1 10.50 usec
PL1 0 dB
PL1W 91.93504333 W
SFO1 150.9505906 MHz

===== CHANNEL f2 =====
CPDPRG2 waltz16
NUC2 1H
PCPD2 90.00 usec
PL2 -3.00 dB
PL12 16.26 dB
PL13 18.00 dB
PL2W 30.57242203 W
PL12W 0.36251819 W
PL13W 0.24284537 W
SFO2 600.2624010 MHz

F2 - Processing parameters
SI 32768
SF 150.9354970 MHz
WDW no
SSB 0
LB 0 Hz
GB 0
PC 1.40

¹H NMR of 4




Current Data Parameters
NAME dp-1161n
EXPNO 12
PROCNO 1


F2 - Acquisition Parameters
Date_ 20110606
Time 21.42
INSTRUM spect
PROBHD 5 mm PABBO BB-
PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 12335.526 Hz
FIDRES 0.188225 Hz
AQ 2.6564426 sec
RG 80.6
DW 40.533 usec
DE 8.50 usec
TE 300.0 K
D1 1.00000000 sec
TD0 1

===== CHANNEL f1 =====
NUC1 1H
P1 9.40 usec
PL1 -3.00 dB
PL1W 30.57242203 W
SFO1 600.2637069 MHz

F2 - Processing parameters
SI 32768
SF 600.2600174 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00



¹³C NMR of 4



Current Data Parameters
NAME dp-1161n
EXPNO 10
PROCNO 1


F2 - Acquisition Parameters
Date_ 20110606
Time 21.27
INSTRUM spect
PROBHD 5 mm PABBO BB-
PULPROG zgpg30
TD 65536
SOLVENT CDCl3
NS 1024
DS 4
SWH 36057.691 Hz
FIDRES 0.550197 Hz
AQ 0.9088159 sec
RG 2050
DW 13.867 usec
DE 8.50 usec
TE 301.2 K
D1 2.00000000 sec
D11 0.03000000 sec
TD0 1

===== CHANNEL f1 =====
NUC1 13C
P1 10.50 usec
PL1 0 dB
PL1W 91.93504333 W
SFO1 150.9505906 MHz

===== CHANNEL f2 =====
CPDPRG2 waltz16
NUC2 1H
PCPD2 90.00 usec
PL2 -3.00 dB
PL12 16.26 dB
PL13 18.00 dB
PL2W 30.57242203 W
PL12W 0.36251819 W
PL13W 0.24284537 W
SFO2 600.2624010 MHz

F2 - Processing parameters
SI 32768
SF 150.9354970 MHz
WDW no
SSB 0
LB 0 Hz
GB 0
PC 1.40

¹H NMR of **5**




Current Data Parameters
NAME dp-11-051
EXPNO 12
PROCNO 1

F2 - Acquisition Parameters
Date_ 20111212
Time 20.52
INSTRUM spect
PROBHD 5 mm PABBO BB-
PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 12335.526 Hz
FIDRES 0.188225 Hz
AQ 2.6564426 sec
RG 203
DW 40.533 usec
DE 8.50 usec
TE 302.0 K
D1 1.00000000 sec
TD0 1

===== CHANNEL f1 =====
NUC1 1H
P1 9.40 usec
PL1 -3.00 dB
PL1W 30.57242203 W
SFO1 600.2637069 MHz

F2 - Processing parameters
SI 32768
SF 600.2600174 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00

¹³C NMR of 5



Current Data Parameters
NAME dp-11-051
EXPNO 10
PROCNO 1


F2 - Acquisition Parameters
Date_ 20111212
Time_ 20.38
INSTRUM spect
PROBHD 5 mm PABBO BB-
PULPROG zgpg30
TD 65536
SOLVENT CDC13
NS 1024
DS 4
SWH 36057.691 Hz
FIDRES 0.550197 Hz
AQ 0.9088159 sec
RG 2050
DW 13.867 usec
DE 8.50 usec
TE 302.0 K
D1 2.00000000 sec
D11 0.03000000 sec
TD0 1

===== CHANNEL f1 =====
NUC1 13C
P1 10.50 usec
PL1 0 dB
PL1W 91.93504333 W
SFO1 150.9505906 MHz

===== CHANNEL f2 =====
CPDPRG2 waltz16
NUC2 1H
PCPD2 90.00 usec
PL2 -3.00 dB
PL12 16.26 dB
PL13 18.00 dB
PL2W 30.57242203 W
PL12W 0.36251819 W
PL13W 0.24284537 W
SFO2 600.2624010 MHz

F2 - Processing parameters
SI 32768
SF 150.9354970 MHz
WDW no
SSB 0
LB 0 Hz
GB 0
PC 1.40

¹H NMR of 6




Current Data Parameters
NAME dp-11-053
EXPNO 12
PROCNO 1

F2 - Acquisition Parameters
Date_ 20111213
Time 16.00
INSTRUM spect
PROBHD 5 mm PABBO BB-
PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 12335.526 Hz
FIDRES 0.188225 Hz
AQ 2.6564426 sec
RG 181
DW 40.533 usec
DE 8.50 usec
TE 301.9 K
D1 1.0000000 sec
TD0 1

===== CHANNEL f1 =====
NUC1 1H
P1 9.40 usec
PL1 -3.00 dB
PL1W 30.57242203 W
SFO1 600.2637069 MHz

F2 - Processing parameters
SI 32768
SF 600.2600174 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00

¹³C NMR of 6



Current Data Parameters
NAME dp-11-053
EXPNO 10
PROCNO 1


F2 - Acquisition Parameters
Date_ 20111213
Time 15.45
INSTRUM spect
PROBHD 5 mm PABBO BB-
PULPROG zgpg30
TD 65536
SOLVENT CDCl3
NS 1024
DS 4
SWH 36057.691 Hz
FIDRES 0.550197 Hz
AQ 0.9088159 sec
RG 2050
DW 13.867 usec
DE 8.50 usec
TE 302.0 K
D1 2.00000000 sec
D11 0.03000000 sec
TD0 1

===== CHANNEL f1 =====
NUC1 13C
P1 10.50 usec
PL1 0 dB
PL1W 91.93504333 W
SFO1 150.9505906 MHz

===== CHANNEL f2 =====
CPDPRG2 waltz16
NUC2 1H
PCPD2 90.00 usec
PL2 -3.00 dB
PL12 16.26 dB
PL13 18.00 dB
PL2W 30.57242203 W
PL12W 0.36251819 W
PL13W 0.24284537 W
SFO2 600.2624010 MHz


F2 - Processing parameters
SI 32768
SF 150.9354970 MHz
WDW no
SSB 0
LB 0 Hz
GB 0
PC 1.40

MALDI-MS for 3




D.Plazuk, DP 11-052 (MeOH), [CHCA, a-cyano-4-hydroxycinnamic acid - saturated in 0,1% TFA H₂O / ACN - 1:1]
E:\...ven930003.dat
Acquired: 11:25:00, December 21, 2011

MALDI-MS for 4




D.Plazuk, DP 1161 (MeOH), [CHCA, a-cyano-4-hydroxycinnaminic acid - saturated in 0,1% TFA H2O / ACN - 1:1]
E:\...ven950003.dat
Acquired: 11:20:00, December 21, 2011

MALDI-MS for 5



D.Plazuk, DP 11-051 (MeOH), [CHCA, a-cyano-4-hydroxycinnaminic acid - saturated in 0,1% TFA H2O / ACN - 1:1]
E:\...ven920002.dat
Acquired: 11:28:00, December 21, 2011

MALDI-MS for 6



D.Plazuk, DP 11-053 (MeOH), [CHCA, a-cyano-4-hydroxycinnaminic acid - saturated in 0,1% TFA H2O / ACN - 1:1]
E:\...ven940001.dat
Acquired: 11:21:00, December 21, 2011